HYUNDAI BIOSCIENCE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21,100 KRW | +1.44% |
|
+2.18% | -19.16% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 182,744 | 486,740 | 1,048,678 | 976,101 | 1,087,244 | 1,038,982 |
| Enterprise Value (EV) 1 | 188,850 | 493,159 | 1,066,601 | 969,389 | 1,074,761 | 1,032,717 |
| P/E ratio | 69.8 x | 634 x | -127 x | -46.5 x | -68.2 x | -71.5 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 5.74 x | 16.2 x | 83.8 x | 106 x | 138 x | 110 x |
| EV / Revenue | 5.93 x | 16.4 x | 85.3 x | 105 x | 137 x | 109 x |
| EV / EBITDA | 67.2 x | 79.1 x | -1,635 x | -147 x | -43.8 x | -123 x |
| EV / FCF | -80.9 x | -138 x | -49.6 x | 725 x | -128 x | -211 x |
| FCF Yield | -1.24% | -0.73% | -2.02% | 0.14% | -0.78% | -0.47% |
| Price to Book | 4.51 x | 10.4 x | 20 x | 15.9 x | 18.7 x | 23 x |
| Nbr of stocks (in thousands) | 33,717 | 34,643 | 35,914 | 38,657 | 39,680 | 39,808 |
| Reference price 2 | 5,420 | 14,050 | 29,200 | 25,250 | 27,400 | 26,100 |
| Announcement Date | 3/15/19 | 3/13/20 | 3/17/21 | 3/21/22 | 3/20/23 | 3/6/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 31,864 | 30,086 | 12,511 | 9,241 | 7,852 | 9,481 |
| EBITDA 1 | 2,809 | 6,233 | -652.3 | -6,586 | -24,529 | -8,369 |
| EBIT 1 | 971.8 | 2,420 | -4,430 | -9,289 | -26,311 | -9,804 |
| Operating Margin | 3.05% | 8.04% | -35.41% | -100.52% | -335.1% | -103.4% |
| Earnings before Tax (EBT) 1 | 2,769 | 1,294 | -7,933 | -19,808 | -16,613 | -14,498 |
| Net income 1 | 2,618 | 767.2 | -8,260 | -20,051 | -15,807 | -14,499 |
| Net margin | 8.22% | 2.55% | -66.02% | -216.97% | -201.33% | -152.92% |
| EPS 2 | 77.64 | 22.15 | -230.0 | -543.2 | -402.0 | -365.0 |
| Free Cash Flow 1 | -2,334 | -3,576 | -21,504 | 1,337 | -8,388 | -4,900 |
| FCF margin | -7.32% | -11.89% | -171.87% | 14.47% | -106.83% | -51.68% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/15/19 | 3/13/20 | 3/17/21 | 3/21/22 | 3/20/23 | 3/6/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 6,106 | 6,419 | 17,923 | - | - | - |
| Net Cash position 1 | - | - | - | 6,712 | 12,483 | 6,265 |
| Leverage (Debt/EBITDA) | 2.174 x | 1.03 x | -27.48 x | - | - | - |
| Free Cash Flow 1 | -2,334 | -3,576 | -21,504 | 1,337 | -8,388 | -4,900 |
| ROE (net income / shareholders' equity) | 7.34% | 2.78% | -16.5% | -35.2% | -26.4% | -28% |
| ROA (Net income/ Total Assets) | 1.17% | 2.58% | -3.51% | -6.66% | -22.2% | -10.2% |
| Assets 1 | 223,087 | 29,738 | 235,627 | 300,932 | 71,064 | 142,121 |
| Book Value Per Share 2 | 1,201 | 1,356 | 1,457 | 1,593 | 1,468 | 1,137 |
| Cash Flow per Share 2 | 93.80 | 160.0 | 535.0 | 238.0 | 68.90 | 45.50 |
| Capex 1 | 7,112 | 3,065 | 25,204 | 3,747 | 1,544 | 540 |
| Capex / Sales | 22.32% | 10.19% | 201.45% | 40.54% | 19.66% | 5.69% |
| Announcement Date | 3/15/19 | 3/13/20 | 3/17/21 | 3/21/22 | 3/20/23 | 3/6/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -20.31% | 615M | |
| +14.56% | 396B | |
| +13.13% | 142B | |
| +18.59% | 77.56B | |
| -12.68% | 65.94B | |
| -4.32% | 43.2B | |
| +6.15% | 35.03B | |
| +11.04% | 18.17B | |
| +14.54% | 15.96B | |
| -3.71% | 11.51B |
- Stock Market
- Equities
- A048410 Stock
- Financials Hyundai Bioscience Co., Ltd.
